annual cash & cash equivalents:
$94.86M-$18.17M(-16.07%)Summary
- As of today (July 1, 2025), CYTK annual cash & cash equivalents is $94.86 million, with the most recent change of -$18.17 million (-16.07%) on December 31, 2024.
- During the last 3 years, CYTK annual cash & cash equivalents has fallen by -$17.81 million (-15.81%).
- CYTK annual cash & cash equivalents is now -24.24% below its all-time high of $125.21 million, reached on December 31, 2017.
Performance
CYTK Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$73.68M-$21.18M(-22.33%)Summary
- As of today (July 1, 2025), CYTK quarterly cash & cash equivalents is $73.68 million, with the most recent change of -$21.18 million (-22.33%) on March 1, 2025.
- Over the past year, CYTK quarterly cash & cash equivalents has dropped by -$46.30 million (-38.59%).
- CYTK quarterly cash & cash equivalents is now -63.31% below its all-time high of $200.81 million, reached on September 30, 2020.
Performance
CYTK quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CYTK Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -16.1% | -38.6% |
| 3 y3 years | -15.8% | -36.2% |
| 5 y5 years | +160.4% | +48.0% |
CYTK Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -16.1% | +44.6% | -61.3% | +57.1% |
| 5 y | 5-year | -16.1% | +160.4% | -63.3% | +98.3% |
| alltime | all time | -24.2% | +763.0% | -63.3% | +726.4% |
CYTK Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $73.68M(-22.3%) |
| Dec 2024 | $94.86M(-16.1%) | $94.86M(+102.3%) |
| Sep 2024 | - | $46.89M(-75.3%) |
| Jun 2024 | - | $190.14M(+58.5%) |
| Mar 2024 | - | $119.98M(+6.2%) |
| Dec 2023 | $113.02M(+72.3%) | $113.02M(+13.4%) |
| Sep 2023 | - | $99.69M(+45.2%) |
| Jun 2023 | - | $68.64M(-32.5%) |
| Mar 2023 | - | $101.62M(+54.9%) |
| Dec 2022 | $65.58M(-41.8%) | $65.58M(-38.3%) |
| Sep 2022 | - | $106.24M(+13.5%) |
| Jun 2022 | - | $93.63M(-18.9%) |
| Mar 2022 | - | $115.42M(+2.4%) |
| Dec 2021 | $112.67M(+35.8%) | $112.67M(+24.4%) |
| Sep 2021 | - | $90.56M(+143.7%) |
| Jun 2021 | - | $37.15M(-16.7%) |
| Mar 2021 | - | $44.59M(-46.3%) |
| Dec 2020 | $82.98M(+127.8%) | $82.98M(-58.7%) |
| Sep 2020 | - | $200.81M(+228.5%) |
| Jun 2020 | - | $61.13M(+22.8%) |
| Mar 2020 | - | $49.78M(+36.6%) |
| Dec 2019 | $36.43M(-13.8%) | $36.43M(-8.1%) |
| Sep 2019 | - | $39.63M(+15.3%) |
| Jun 2019 | - | $34.36M(-12.8%) |
| Mar 2019 | - | $39.41M(-6.7%) |
| Dec 2018 | $42.26M(-66.3%) | $42.26M(+53.0%) |
| Sep 2018 | - | $27.62M(-41.2%) |
| Jun 2018 | - | $46.95M(-59.2%) |
| Mar 2018 | - | $115.01M(-8.1%) |
| Dec 2017 | $125.21M(+87.2%) | $125.21M(+7.6%) |
| Sep 2017 | - | $116.32M(+15.5%) |
| Jun 2017 | - | $100.71M(+104.0%) |
| Mar 2017 | - | $49.36M(-26.2%) |
| Dec 2016 | $66.87M(+2.8%) | $66.87M(+120.7%) |
| Sep 2016 | - | $30.30M(+9.3%) |
| Jun 2016 | - | $27.72M(-34.4%) |
| Mar 2016 | - | $42.27M(-35.0%) |
| Dec 2015 | $65.08M(+221.9%) | $65.08M(+150.7%) |
| Sep 2015 | - | $25.96M(+4.5%) |
| Jun 2015 | - | $24.84M(+10.2%) |
| Mar 2015 | - | $22.55M(+11.5%) |
| Dec 2014 | $20.21M | $20.21M(+56.6%) |
| Sep 2014 | - | $12.91M(+4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $12.36M(-6.8%) |
| Mar 2014 | - | $13.26M(-34.2%) |
| Dec 2013 | $20.16M(+35.2%) | $20.16M(+4.7%) |
| Sep 2013 | - | $19.26M(+12.9%) |
| Jun 2013 | - | $17.06M(+29.6%) |
| Mar 2013 | - | $13.16M(-11.7%) |
| Dec 2012 | $14.91M(-20.8%) | $14.91M(-3.1%) |
| Sep 2012 | - | $15.39M(-75.8%) |
| Jun 2012 | - | $63.65M(+257.3%) |
| Mar 2012 | - | $17.82M(-5.4%) |
| Dec 2011 | $18.83M(+7.5%) | $18.83M(+1.3%) |
| Sep 2011 | - | $18.59M(-21.8%) |
| Jun 2011 | - | $23.77M(+53.8%) |
| Mar 2011 | - | $15.45M(-11.8%) |
| Dec 2010 | $17.51M(-31.5%) | $17.51M(-42.5%) |
| Sep 2010 | - | $30.44M(+65.7%) |
| Jun 2010 | - | $18.36M(-11.3%) |
| Mar 2010 | - | $20.71M(-19.0%) |
| Dec 2009 | $25.56M(-38.9%) | $25.56M(+7.8%) |
| Sep 2009 | - | $23.71M(-72.1%) |
| Jun 2009 | - | $85.03M(+75.4%) |
| Mar 2009 | - | $48.49M(+15.9%) |
| Dec 2008 | $41.82M(-64.1%) | $41.82M(-40.8%) |
| Sep 2008 | - | $70.64M(-18.7%) |
| Jun 2008 | - | $86.86M(-17.7%) |
| Mar 2008 | - | $105.54M(-9.5%) |
| Dec 2007 | $116.56M(+195.9%) | $116.56M(+7.4%) |
| Sep 2007 | - | $108.49M(-2.5%) |
| Jun 2007 | - | $111.22M(+6.9%) |
| Mar 2007 | - | $104.05M(+164.2%) |
| Dec 2006 | $39.39M(+191.4%) | $39.39M(-18.3%) |
| Sep 2006 | - | $48.21M(-3.1%) |
| Jun 2006 | - | $49.77M(-31.9%) |
| Mar 2006 | - | $73.11M(+441.0%) |
| Dec 2005 | $13.52M(+3.5%) | $13.52M(+14.5%) |
| Sep 2005 | - | $11.80M(+8.2%) |
| Jun 2005 | - | $10.91M(-26.4%) |
| Mar 2005 | - | $14.82M(+13.4%) |
| Dec 2004 | $13.06M(+18.8%) | $13.06M(-34.0%) |
| Sep 2004 | - | $19.77M(+12.0%) |
| Jun 2004 | - | $17.65M(+98.0%) |
| Mar 2004 | - | $8.92M(-18.9%) |
| Dec 2003 | $10.99M(-32.9%) | $10.99M |
| Dec 2002 | $16.39M | - |
FAQ
- What is Cytokinetics Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated annual cash & cash equivalents year-on-year change?
- What is Cytokinetics Incorporated quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated quarterly cash & cash equivalents year-on-year change?
What is Cytokinetics Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of CYTK is $94.86M
What is the all time high annual cash & cash equivalents for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high annual cash & cash equivalents is $125.21M
What is Cytokinetics Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, CYTK annual cash & cash equivalents has changed by -$18.17M (-16.07%)
What is Cytokinetics Incorporated quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CYTK is $73.68M
What is the all time high quarterly cash & cash equivalents for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high quarterly cash & cash equivalents is $200.81M
What is Cytokinetics Incorporated quarterly cash & cash equivalents year-on-year change?
Over the past year, CYTK quarterly cash & cash equivalents has changed by -$46.30M (-38.59%)